QTc Prolongation , Torsades de Pointes , and Psychotropic Transmural ischemia induced by balloon occlusion ( average total occlusion time , 40 secondsresultedin QTc interval prolongation
Other medicines ... have also been foundto causeQTc interval prolongation
Bazetts formula or use of medicationsmay causeQTc interval prolongation
Bazett s formula or use of medicationsmay causeQTc interval prolongation
Both azithromycin and methadonecan causeQTc interval prolongation
Oral methadonecausesprolongation of QTC interval
tyrosine kinase inhibitors ' , British Journal of Cancer(passive) caused byQTc - interval prolongation
tyrosine kinase inhibitors in BRITISH JOURNAL OF CANCER 2010 - 02(passive) caused byQTc - interval prolongation
the administration of various drugs and drug combinationscausingprolongation of the QTc interval
often - prescribed drugscausingQTc interval prolongation
Amphetamines ... lists of drugscauseQTc interval prolongation
tyrosine kinase inhibitors AU - Verboom , M. C. AU - Kruit , W. H(passive) caused byQTc - interval prolongation
Many medications commonly prescribed in psychiatric hospitalscan causeQTc - interval prolongation
tyrosine kinase inhibitors by Kloth , Jacqueline and Pagani , A and Verboom , Michiel and Malovini , A and Napolitano , C and Kruit , Wim and Sleijfer , Stefan and Steeghs , Neeltje and Zambelli , A and Mathijssen , Ron British Journal of Cancer , ISSN 0007 - 0920 , 01/2015 , Volume 112(passive) caused byQTc - interval prolongation
History of familial long QT syndrome , or use of medicationsmay causeQTc interval prolongation
Warnings & Recalls for Ranexa Ranexa has been under scrutiny due to its potential for altering the heartbeatresultingin QTc interval prolongation
several factors , one of which is hypothermia.1(passive) can be caused byProlongation of the QTc interval
food and drug therapy likelyto cause qtinterval prolongation
tyrosine kinase inhibitors — Italian Ministry of Health J. S L Kloth , A. Pagani , M. C. Verboom , A. Malovini , C. Napolitano , W. H J Kruit , S. Sleijfer , N. Steeghs , A. Zambelli , R. H J Mathijssen Background(passive) caused byQTc - interval prolongation
intracranial or epidural disease , background of macular degeneration or blindness in a single eyesight , or any various other ocular Rabbit Polyclonal to OGFR diagnosis where in fact the benefit - risk proportion would favour exclusion through the trial ; nonsecretory or biclonal MM ; known hypersensitivity to boron or mannitol ; preceding treatment with any Hsp90 inhibitor ; quality 1 sensory and/or electric motor neuropathy ; known HIV disease or AIDS - related disease , known hepatitis B or C or various other active liver organ disease , and energetic herpes zoster disease ( people that have a prior background of herpes zoster disease had been permitted entry in to the trial if treated with prophylactic acyclovir unless contraindicated ) ; being pregnant or breast - feeding ; usage of immunosuppressive therapy apart from corticosteroids at a dosage equal to dexamethasone ? 2.5?mg?d?1 ; usage of medication recognizedto commonly triggerQTc interval prolongation
BedaquilinecausesQTcF interval prolongation
ZYKADIAcan causeQTc interval prolongation
any concomitant medication knownto commonly causeQTc interval prolongation
Both azithromycin and high dose loperamidecan causeQTc interval prolongation
The results showcausesprolongation of QTc interval
Both azithromycin and cocainecan causeQTc interval prolongation
Common side effects of SSRIs include insomnia and gastrointestinal discomfortmay ... causeprolongation of the QTc interval
the use of droperidol(passive) caused byQTc interval prolongation
Quinolones пBecause quinolonescan causeprolongation of the QTc - interval
transient drug discontinuationpromptingtransient drug discontinuation
to potentially fatal arrhythmiascan leadto potentially fatal arrhythmias
to an increased risk for ventricular tachyarrhythmias ( e.g. , Torsade de pointes ) or sudden death , occurred in patients treated with Zykadia in clinical trialsmay leadto an increased risk for ventricular tachyarrhythmias ( e.g. , Torsade de pointes ) or sudden death , occurred in patients treated with Zykadia in clinical trials
to torsades de pointes ( TdPcan leadto torsades de pointes ( TdP
in ventricular arrhythmias , torsade de pointes , and sudden death SAN DIEGOcan resultin ventricular arrhythmias , torsade de pointes , and sudden death SAN DIEGO
to cardiovascular consequences , including heart block or cardiac arrhythmiasmay leadto cardiovascular consequences , including heart block or cardiac arrhythmias
to an increased risk for ventricular tachyarrhythmia ( e.g. , torsades de pointesmay leadto an increased risk for ventricular tachyarrhythmia ( e.g. , torsades de pointes
fatal cardiac arrhythmias of a type called � torsade des pointescan causefatal cardiac arrhythmias of a type called � torsade des pointes
to Torsade de Pointes ( TdP ) , a potentially life - threatening cardiac arrhythmiacan leadto Torsade de Pointes ( TdP ) , a potentially life - threatening cardiac arrhythmia
in the worst prognosis for menresultedin the worst prognosis for men
life - threatening polymorphic ventricular tachycardia also known as torsade de pointescan causelife - threatening polymorphic ventricular tachycardia also known as torsade de pointes
32449208[PubMed - as supplied by publisher ... QTc interval prolongation ... to life - threatening complications such as torsade de pointes ( TdP ) , ventricular tachycardia ( VT ) , and sudden cardiac death ( SCDcan lead32449208[PubMed - as supplied by publisher ... QTc interval prolongation ... to life - threatening complications such as torsade de pointes ( TdP ) , ventricular tachycardia ( VT ) , and sudden cardiac death ( SCD
in Torsade de Pointes , a ventricular arrhythmiamay resultin Torsade de Pointes , a ventricular arrhythmia
to fatal ventricular arrhythmias and sudden cardiac deathleadsto fatal ventricular arrhythmias and sudden cardiac death